Building the next generation of global leaders in life science

We found, build and fund companies to translate exceptional science into transformational treatments for patients in areas of high unmet need.

Who we are

Syncona domain expertise

Our deep expertise in four key modalities enables the rapid translation of scientific research into companies with the potential to be global leaders and the development of a diversified portfolio of 15-20 companies

Making a positive contribution

We are committed to managing our business in a sustainable way, investing responsibly, and supporting our portfolio companies in making positive contributions to society by developing treatments that will make a difference to the lives of patients and their families.

Annual Report and Accounts 2022 front cover

Annual Report and Accounts 2022

Our Annual Report and Accounts 2022 provides an overview of our most recent financial year, as we look to deliver on behalf of our stakeholders.

30.06.22 | pdf (7.22Mb)

An expert multi-disciplinary team, attracting world-class talent

We are differentiated by our people, who identify innovative technology and take a commercial approach to building businesses capable of delivering transformational treatments to patients.

Our people

Leadership key facts*


Members of the investment team


Years of life science and investment expertise


Investment team with PhDs or M.D.s

*All as of 31 March 2022